Advisory board

Promethera® Biosciences scientific strategy is based on the advice of a distinguished panel of international experts in cell therapy and liver disease.

Promethera® Biosciences’ Scientific Advisory Board is comprised of seven independent, internationally renowned key opinion leaders in hepatology and liver research.

It works closely with Promethera® Biosciences to support its management team and board of directors, providing strategic, scientific and medical advice on various clinical applications of its technologies for a broad range of liver diseases .


  • Cell engraftment, the acceptance of transplanted cells which then express enzyme activity
  • Cell encapsulation in biopolymeric membranes which permits cell activity while protecting them from destruction by the host’s immune system
  • Cell editing or re-programming to provide altered function
  • Maintenance and expansion of specific cells
  • Clinical translation of certain features of Promethera® Biosciences’ cells to treat liver diseases
  • Development of relevant small and large animal models.

Etienne Sokal – MD, PhD

Senior Scientific & Medical Advisor
Chairman of the SMAB & the Board of Directors

Massimo Pinzani – MD, PhD, FRCP


Anil Dhawan – MD, FRCPCH


Sanjeev Gupta – MBBS, MD, FRCP, FACP, FAASLD


Michael Ott – MD


Andreas Nuessler – PhD


Massimo Dominici – MD


Scott L. Friedman – MD


Dr. Mustapha Najimi has been part of Promethera® Biosciences since its foundation and is co-inventor of 2 patents on Heterologous Human Adult Live Progenitor Cells (HHALPC). He provides his valuable expertise to the Promethera® team as a special scientific advisor.

Mustapha Najimi – PhD

Special Advisor – Scientific Affairs